{"result": {"id": "98846feb-4198-4ebf-b213-d3cf68ec222e", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>中华医学会老年医学分会<|>ORGANIZATION<|>The Geriatrics Branch of the Chinese Medical Association focusing on elderly health and diseases)\n##\n(\"entity\"<|>《中华内科杂志》编辑委员会<|>ORGANIZATION<|>Editorial board of Chinese Journal of Internal Medicine publishing internal medicine research)\n##\n(\"entity\"<|>《中华老年医学杂志》编辑委员会<|>ORGANIZATION<|>Editorial board of Chinese Journal of Geriatrics focusing on aging research)\n##\n(\"entity\"<|>Collins R<|>PERSON<|>Researcher involved in meta-analysis of aspirin use in vascular disease prevention)\n##\n(\"entity\"<|>Benjamin EJ<|>PERSON<|>Researcher involved in cardiovascular disease prevention guidelines)\n##\n(\"entity\"<|>Bonow RO<|>PERSON<|>Researcher involved in cardiovascular disease prevention guidelines)\n##\n(\"entity\"<|>Hoes AW<|>PERSON<|>Researcher involved in European cardiovascular prevention guidelines)\n##\n(\"entity\"<|>Agewall S<|>PERSON<|>Researcher involved in European cardiovascular prevention guidelines)\n##\n(\"entity\"<|>Mafham M<|>PERSON<|>Researcher studying aspirin effects in diabetes patients)\n##\n(\"entity\"<|>Wallendszus K<|>PERSON<|>Researcher studying aspirin effects in diabetes patients)\n##\n(\"entity\"<|>Brotons C<|>PERSON<|>Researcher involved in aspirin trials for cardiovascular prevention)\n##\n(\"entity\"<|>Coppolecchia R<|>PERSON<|>Researcher involved in aspirin trials for cardiovascular prevention)\n##\n(\"entity\"<|>Gad MM<|>PERSON<|>Researcher involved in meta-analysis of aspirin for primary prevention)\n##\n(\"entity\"<|>Elgendy AY<|>PERSON<|>Researcher involved in meta-analysis of aspirin for primary prevention)\n##\n(\"entity\"<|>Wolfe R<|>PERSON<|>Researcher studying aspirin effects in elderly patients)\n##\n(\"entity\"<|>Woods RL<|>PERSON<|>Researcher studying aspirin effects in elderly patients)\n##\n(\"entity\"<|>Burda BU<|>PERSON<|>Researcher involved in systematic review of aspirin bleeding risks)\n##\n(\"entity\"<|>Williams SB<|>PERSON<|>Researcher involved in systematic review of aspirin bleeding risks)\n##\n(\"entity\"<|>Tang Y<|>PERSON<|>Researcher involved in atrial fibrillation epidemiological study in China)\n##\n(\"entity\"<|>Zhao Q<|>PERSON<|>Researcher involved in atrial fibrillation epidemiological study in China)\n##\n(\"entity\"<|>Honarbakhsh S<|>PERSON<|>Researcher involved in atrial fibrillation risk factor studies)\n##\n(\"entity\"<|>Casas JP<|>PERSON<|>Researcher involved in atrial fibrillation risk factor studies)\n##\n(\"entity\"<|>Potpara T<|>PERSON<|>Researcher involved in ESC atrial fibrillation guidelines)\n##\n(\"entity\"<|>Dagres N<|>PERSON<|>Researcher involved in ESC atrial fibrillation guidelines)\n##\n(\"entity\"<|>Ezekowitz MD<|>PERSON<|>Researcher involved in atrial fibrillation treatment studies)\n##\n(\"entity\"<|>Yusuf S<|>PERSON<|>Researcher involved in atrial fibrillation treatment studies)\n##\n(\"entity\"<|>Mahaffey KW<|>PERSON<|>Researcher involved in atrial fibrillation treatment studies)\n##\n(\"entity\"<|>Garg J<|>PERSON<|>Researcher involved in atrial fibrillation treatment studies)\n##\n(\"entity\"<|>Alexander JH<|>PERSON<|>Researcher involved in atrial fibrillation treatment studies)\n##\n(\"entity\"<|>McMurray JJ<|>PERSON<|>Researcher involved in atrial fibrillation treatment studies)\n##\n(\"entity\"<|>Ruff CT<|>PERSON<|>Researcher involved in atrial fibrillation treatment studies)\n##\n(\"entity\"<|>Braunwald E<|>PERSON<|>Researcher involved in atrial fibrillation treatment studies)\n##\n(\"relationship\"<|>中华医学会老年医学分会<|>《中华内科杂志》编辑委员会<|>Collaborated on Chinese expert consensus for aspirin use in cardiovascular disease<|>8)\n##\n(\"relationship\"<|>中华医学会老年医学分会<|>《中华老年医学杂志》编辑委员会<|>Collaborated on Chinese expert consensus for aspirin use in cardiovascular disease<|>8)\n##\n(\"relationship\"<|>Collins R<|>Baigent C<|>Co-authors on meta-analysis of aspirin use in vascular disease prevention<|>9)\n##\n(\"relationship\"<|>Benjamin EJ<|>Smith SC Jr<|>Co-authors on cardiovascular disease prevention guidelines<|>9)\n##\n(\"relationship\"<|>Bonow RO<|>Smith SC Jr<|>Co-authors on cardiovascular disease prevention guidelines<|>9)\n##\n(\"relationship\"<|>Hoes AW<|>Piepoli MF<|>Co-authors on European cardiovascular prevention guidelines<|>9)\n##\n(\"relationship\"<|>Agewall S<|>Piepoli MF<|>Co-authors on European cardiovascular prevention guidelines<|>9)\n##\n(\"relationship\"<|>Mafham M<|>Bowman L<|>Co-authors on aspirin study in diabetes patients<|>9)\n##\n(\"relationship\"<|>Wallendszus K<|>Bowman L<|>Co-authors on aspirin study in diabetes patients<|>9)\n##\n(\"relationship\"<|>Brotons C<|>Gaziano JM<|>Co-authors on aspirin trial for cardiovascular prevention<|>9)\n##\n(\"relationship\"<|>Coppolecchia R<|>Gaziano JM<|>Co-authors on aspirin trial for cardiovascular prevention<|>9)\n##\n(\"relationship\"<|>Gad MM<|>Mahmoud AN<|>Co-authors on meta-analysis of aspirin for primary prevention<|>9)\n##\n(\"relationship\"<|>Elgendy AY<|>Mahmoud AN<|>Co-authors on meta-analysis of aspirin for primary prevention<|>9)\n##\n(\"relationship\"<|>Wolfe R<|>McNeil JJ<|>Co-authors on aspirin study in elderly patients<|>9)\n##\n(\"relationship\"<|>Woods RL<|>McNeil JJ<|>Co-authors on aspirin study in elderly patients<|>9)\n##\n(\"relationship\"<|>Burda BU<|>Whitlock EP<|>Co-authors on systematic review of aspirin bleeding risks<|>9)\n##\n(\"relationship\"<|>Williams SB<|>Whitlock EP<|>Co-authors on systematic review of aspirin bleeding risks<|>9)\n##\n(\"relationship\"<|>Tang Y<|>Shi S<|>Co-authors on atrial fibrillation study in China<|>9)\n##\n(\"relationship\"<|>Zhao Q<|>Shi S<|>Co-authors on atrial fibrillation study in China<|>9)\n##\n(\"relationship\"<|>Honarbakhsh S<|>Allan V<|>Co-authors on atrial fibrillation risk factor study<|>9)\n##\n(\"relationship\"<|>Casas JP<|>Allan V<|>Co-authors on atrial fibrillation risk factor study<|>9)\n##\n(\"relationship\"<|>Potpara T<|>Hindricks G<|>Co-authors on ESC atrial fibrillation guidelines<|>9)\n##\n(\"relationship\"<|>Dagres N<|>Hindricks G<|>Co-authors on ESC atrial fibrillation guidelines<|>9)\n##\n(\"relationship\"<|>Ezekowitz MD<|>Connolly SJ<|>Co-authors on atrial fibrillation treatment study<|>9)\n##\n(\"relationship\"<|>Yusuf S<|>Connolly SJ<|>Co-authors on atrial fibrillation treatment study<|>9)\n##\n(\"relationship\"<|>Mahaffey KW<|>Patel MR<|>Co-authors on atrial fibrillation treatment study<|>9)\n##\n(\"relationship\"<|>Garg J<|>Patel MR<|>Co-authors on atrial fibrillation treatment study<|>9)\n##\n(\"relationship\"<|>Alexander JH<|>Granger CB<|>Co-authors on atrial fibrillation treatment study<|>9)\n##\n(\"relationship\"<|>McMurray JJ<|>Granger CB<|>Co-authors on atrial fibrillation treatment study<|>9)\n##\n(\"relationship\"<|>Ruff CT<|>Giugliano RP<|>Co-authors on atrial fibrillation treatment study<|>9)\n##\n(\"relationship\"<|>Braunwald E<|>Giugliano RP<|>Co-authors on atrial fibrillation treatment study<|>9)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558987, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1997, "prompt_tokens": 4401, "total_tokens": 6398, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 4352}, "prompt_cache_hit_tokens": 4352, "prompt_cache_miss_tokens": 49}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ]. 中国循环杂志 ,2023,38(3) :237-271.\n[349]  BaigentC, BlackwellL, CollinsR, etal. Aspirinintheprimary and secondarypreventionofvasculardisease: collaborativemeta- analysisofindividualparticipantdatafrom randomisedtrials[J].   Lancet,2009,373(9678) :1849-1860.\n[350]  SmithSCJr, BenjaminEJ, Bonow RO, etal. AHA/ACCF sec- ondaryprevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease:  2011 up- date: a guideline from  the  American Heart Association and American College of Cardiology Foundation[J].  Circulation,  2011,124(22) :2458-2473.\n[351]  PiepoliMF, HoesAW , AgewallS, etal. 2016Europeanguide- linesoncardiovasculardiseasepreventioninclinicalpractice: the sixthjointtaskforceofthe European Society ofCardiology and other societies on cardiovascular disease prevention in clinical practice(constitutedbyrepresentativesof10societiesandbyin- vited experts) developedwiththespecialcontributionoftheEu- ropean Association forCardiovascularPrevention & Rehabilita-\n\n\ntion(EACPR)[J]. EurHeartJ,2016,37(29) :2315-2381.\n[352]  Bowman L, Mafham M, WallendszusK, etal. Effectsofaspi- rin forprimaryprevention in personswithdiabetesmellitus[J].   N EnglJ Med,2018,379(16) :1529-1539.\n[353]  GazianoJM, BrotonsC, CoppolecchiaR, etal. Useofaspirinto reducerisk ofinitialvasculareventsinpatientsatmoderate risk of cardiovascular disease ( ARRIVE) :  a randomised,  double- blind, placebo-controlled trial[J]. Lancet, 2018, 392(10152) :  1036-1046.\n[354]  MahmoudAN, GadMM, ElgendyAY, etal. Efficacyandsafe- tyofaspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized con- trolledtrials[J]. EurHeartJ,2019,40(7) :607-617.\n[355]  McNeilJJ, WolfeR, WoodsRL, etal. Effectofaspirinon car- diovasculareventsandbleedinginthehealthyelderly[J]. N Engl JMed,2018,379(16) :1509-1518.\n[356]  Whitlock EP, Burda BU, WilliamsSB, et al.  Bleeding risks with aspirin use for primary prevention in adults: a systematic review forthe U. S.  preventive services taskforce[J]. Ann In- tern Med,2016,164(12) :826-835.\n[357]  中华医学会老年医学分会 ,《中华内科杂志》编辑委员会 ,《中华 老年医学杂志》编辑委员会.  阿司匹林在动脉粥样硬化性心血管 疾病中的临床应用 : 中国专家共识(2016) [J]. 中华内科杂志 , 2017,56(1) :68-80.\n[358]  ShiS, TangY, Zhao Q, etal. Prevalence and risk ofatrialfi- brillation in China:  a national cross-sectional epidemiological study[J]. LancetReg HealthWestPac,2022,23:100439.\n[359]  Allan V, Honarbakhsh S, Casas JP, et al.  Are cardiovascular risk factors also associated with the incidence of atrialfibrilla- tion? A systematicreview and field synopsis of23factors in32 population-based cohortsof 20 million participants[J]. Thromb Haemost,2017,117(5) :837-850.\n[360]  HindricksG, PotparaT, DagresN, etal.  2020ESC guidelines forthediagnosisand managementofatrialfibrillation developed incollaborationwiththeEuropeanAssociationofCardio-Thorac- icSurgery(EACTS)[J]. EurHeartJ,2021,42(5) :373-498.\n[361]  ConnollySJ, EzekowitzMD, YusufS, etal. Dabigatran versus warfarin in patients with atrialfibrillation[J]. N EnglJ Med,  2009,361(12) :1139-1151.\n[362]  Patel MR, Mahaffey KW , GargJ,  et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N EnglJ Med,  2011,365(10) :883-891.\n[363]  GrangerCB, AlexanderJH, McMurrayJJ, etal. Apixabanver- suswarfarininpatientswithatrialfibrillation[J]. NEnglJMed,  2011,365(11) :981-992.\n[364]  GiuglianoRP, RuffCT, BraunwaldE, etal.  Edo\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>中国循环杂志<|>ORGANIZATION<|>A Chinese medical journal publishing research on cardiovascular diseases and related topics)\n##\n(\"entity\"<|>Lancet<|>ORGANIZATION<|>A prestigious international medical journal publishing high-impact research and reviews)\n##\n(\"entity\"<|>American Heart Association<|>ORGANIZATION<|>A leading organization focused on cardiovascular health and research in the United States)\n##\n(\"entity\"<|>American College of Cardiology Foundation<|>ORGANIZATION<|>A professional organization dedicated to improving cardiovascular care through education and research)\n##\n(\"entity\"<|>European Society of Cardiology<|>ORGANIZATION<|>A leading European organization focused on cardiovascular medicine and research)\n##\n(\"entity\"<|>European Association for Cardiovascular Prevention & Rehabilitation<|>ORGANIZATION<|>An organization focused on cardiovascular disease prevention and rehabilitation in Europe)\n##\n(\"entity\"<|>N Engl J Med<|>ORGANIZATION<|>The New England Journal of Medicine, a highly respected medical journal publishing original research and reviews)\n##\n(\"entity\"<|>Eur Heart J<|>ORGANIZATION<|>The European Heart Journal, a leading journal in cardiovascular medicine)\n##\n(\"entity\"<|>中华医学会老年医学分会<|>ORGANIZATION<|>The Geriatrics Branch of the Chinese Medical Association, focusing on elderly health and diseases)\n##\n(\"entity\"<|>《中华内科杂志》编辑委员会<|>ORGANIZATION<|>The editorial board of the Chinese Journal of Internal Medicine, publishing research on internal medicine)\n##\n(\"entity\"<|>《中华老年医学杂志》编辑委员会<|>ORGANIZATION<|>The editorial board of the Chinese Journal of Geriatrics, focusing on aging and related diseases)\n##\n(\"entity\"<|>Baigent C<|>PERSON<|>A researcher involved in meta-analysis of aspirin use in vascular disease prevention)\n##\n(\"entity\"<|>Smith SC Jr<|>PERSON<|>A researcher involved in guidelines for secondary prevention of cardiovascular diseases)\n##\n(\"entity\"<|>Piepoli MF<|>PERSON<|>A researcher involved in European guidelines on cardiovascular disease prevention)\n##\n(\"entity\"<|>Bowman L<|>PERSON<|>A researcher studying the effects of aspirin in primary prevention for diabetes patients)\n##\n(\"entity\"<|>Gaziano JM<|>PERSON<|>A researcher involved in trials studying aspirin for reducing vascular events)\n##\n(\"entity\"<|>Mahmoud AN<|>PERSON<|>A researcher involved in meta-analysis of aspirin for primary prevention of cardiovascular events)\n##\n(\"entity\"<|>McNeil JJ<|>PERSON<|>A researcher studying the effects of aspirin on cardiovascular events in the elderly)\n##\n(\"entity\"<|>Whitlock EP<|>PERSON<|>A researcher involved in systematic reviews of bleeding risks with aspirin use)\n##\n(\"entity\"<|>Shi S<|>PERSON<|>A researcher involved in epidemiological studies on atrial fibrillation in China)\n##\n(\"entity\"<|>Allan V<|>PERSON<|>A researcher involved in systematic reviews of cardiovascular risk factors and atrial fibrillation)\n##\n(\"entity\"<|>Hindricks G<|>PERSON<|>A researcher involved in ESC guidelines for atrial fibrillation diagnosis and management)\n##\n(\"entity\"<|>Connolly SJ<|>PERSON<|>A researcher involved in studies comparing dabigatran and warfarin in atrial fibrillation patients)\n##\n(\"entity\"<|>Patel MR<|>PERSON<|>A researcher involved in studies comparing rivaroxaban and warfarin in atrial fibrillation patients)\n##\n(\"entity\"<|>Granger CB<|>PERSON<|>A researcher involved in studies comparing apixaban and warfarin in atrial fibrillation patients)\n##\n(\"entity\"<|>Giugliano RP<|>PERSON<|>A researcher involved in studies on anticoagulants for atrial fibrillation)\n##\n(\"relationship\"<|>American Heart Association<|>American College of Cardiology Foundation<|>Collaborated on guidelines for secondary prevention of cardiovascular diseases<|>8)\n##\n(\"relationship\"<|>European Society of Cardiology<|>European Association for Cardiovascular Prevention & Rehabilitation<|>Collaborated on guidelines for cardiovascular disease prevention<|>8)\n##\n(\"relationship\"<|>Baigent C<|>Lancet<|>Published a meta-analysis on aspirin use in vascular disease prevention in Lancet<|>7)\n##\n(\"relationship\"<|>Smith SC Jr<|>American Heart Association<|>Contributed to guidelines published by the American Heart Association<|>7)\n##\n(\"relationship\"<|>Piepoli MF<|>European Society of Cardiology<|>Contributed to European guidelines on cardiovascular disease prevention<|>7)\n##\n(\"relationship\"<|>Bowman L<|>N Engl J Med<|>Published research on aspirin for primary prevention in diabetes patients in N Engl J Med<|>7)\n##\n(\"relationship\"<|>Gaziano JM<|>Lancet<|>Published a trial on aspirin for reducing vascular events in Lancet<|>7)\n##\n(\"relationship\"<|>Mahmoud AN<|>Eur Heart J<|>Published a meta-analysis on aspirin for primary prevention in Eur Heart J<|>7)\n##\n(\"relationship\"<|>McNeil JJ<|>N Engl J Med<|>Published research on aspirin effects in the elderly in N Engl J Med<|>7)\n##\n(\"relationship\"<|>Whitlock EP<|>Ann Intern Med<|>Published a systematic review on bleeding risks with aspirin in Ann Intern Med<|>7)\n##\n(\"relationship\"<|>Shi S<|>Lancet Reg Health West Pac<|>Published an epidemiological study on atrial fibrillation in China in Lancet Reg Health West Pac<|>7)\n##\n(\"relationship\"<|>Hindricks G<|>European Society of Cardiology<|>Contributed to ESC guidelines for atrial fibrillation<|>7)\n##\n(\"relationship\"<|>Connolly SJ<|>N Engl J Med<|>Published a study comparing dabigatran and warfarin in N Engl J Med<|>7)\n##\n(\"relationship\"<|>Patel MR<|>N Engl J Med<|>Published a study comparing rivaroxaban and warfarin in N Engl J Med<|>7)\n##\n(\"relationship\"<|>Granger CB<|>N Engl J Med<|>Published a study comparing apixaban and warfarin in N Engl J Med<|>7)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_671831f265ae0bed155df4a902b7b7cf09e19733f32d4e8df41fb6ffb7df8154_v2"}